EUCTR2021-005787-22-DE进行中（未招募）1 期
A randomised, double-blind, placebo-controlled study to investigate the safety and tolerability of EP395 in patients with chronic obstructive pulmonary disease (COPD)
EpiEndo Pharmaceuticals0 个研究点目标入组 60 人开始时间: 2022年6月7日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Willing and able to understand the information on the nature, the scope, and the relevance of the study, and to provide voluntary, written informed consent to participate in the study before any study-related procedures
- •2. Men and women, aged =45 years
- •3. Women of childbearing potential must:
- •a. have a negative pregnancy test (blood) at Screening and (urine) Day 1
- •b. agree to use, and be able to comply with, highly effective measures of contraceptive control (failure rate less than 1% per year when used consistently and correctly) without interruption, during study participation and until 90 days after the last investigational product (IP) intake.
- •c. agree to abstain from breast feeding during the study participation and for 90 days after the last IP intake.
- •4. Men must agree to use a condom during sexual intercourse with women of childbearing potential during treatment and for 90 days after the last IP intake and should not donate sperm during this time
- •5. Diagnosed with COPD for at least 2 years with FEV1/forced vital capacity (FVC) ratio <0.70 and FEV1 <70% (post bronchodilator) at Screening
- •6. Receiving at least one maintenance inhaled therapy (ie, LABA, LAMA, LABA/LAMA, LABA/ICS, LAMA/ICS, or LABA/LAMA/ICS) for at least 3 months before Screening
- •7. Able to tolerate the sputum induction procedure and to produce an adequate (volume and sufficient quality for cell count) sputum sample
- •8. Body mass index of =19 and =35 kg/m2
- •9. History of sputum production (bronchitic phenotype) for approximately 3 months (minimum, not consecutive) in a year
- •10. Up to date COVID-19 vaccination (according to local law and guidelines)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. History or presence of any clinically relevant medical condition including laboratory test abnormality or planned surgery that in the investigator’s opinion could affect the patient’s safety or interfere with the objectives of the study
- •2. Exacerbation of COPD in the 3 months before Screening
- •3. Change in medication for COPD in the 3 months before Screening
- •4. Lung function at Screening that in the investigator’s opinion would indicate not safe to perform sputum induction or bronchoscopy (bronchoscopy applicable only in a subset of patients)
- •5. History of or active tuberculosis
- •6. Malignancy within the past 5 years, except removed basal cell carcinoma and resected benign colonic polyps
- •7. Clinically significant abnormality on 12-lead ECG including prolonged corrected QTcF (>450 msec in men or >470 msec in women); based on triplicate) at Screening and Day 1 pre-dose
- •8. Absolute estimated glomerular filtration rate ([eGFR cystatin C + eGFR creatinine]/2) <60mL/min according to Lund-Malmö equation at Screening
- •9. AST or ALT >1.5 x ULN at Screening
- •10. Use (including prescription, over-the-counter, herbal or dietary) of cytochrome P450 (CYP) inducers within 28 days before first dosing, or strong or moderate inhibitors of CYP3A4 (including dietary eg, grapefruit juice) or P-glycoprotein (Pgp) inhibitors or oral narrow therapeutic index (TI) Pgp substrates (eg, digoxin) within 14 days before first dosing
- •11. Use of macrolide, roflumilast, or oral corticosteroid (OCS) within 28 days before Screening
- •12. Ongoing antibiotic treatment at Screening
- •13. Use of home oxygen or home-based non-invasive ventilation 3 months before Screening
- •14. Use of a biological therapy within 3 months before Screening
- •15. Use of herbal remedies within 28 days before first dose until follow up
- •16. Live vaccine within 28 days or any other vaccine within 14 days before first dose until 28 days after final dose of the IP (with the exception of COVID-19 booster and flu vaccination; see Previous and concomitant medications and therapies)
- •17. Positive hepatitis B surface antigen, hepatitis C antibodies, or human immunodeficiency virus 1 or 2 antibodies at Screening
- •18. Positive test result for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) on Day 1
- •19. Positive drugs of abuse test at Screening, including cotinine only in ex-smokers for at least 3 months
- •20. Use of e-cigarettes and vapes
- •21. History of alcohol or drug misuse within 12 months before Screening
- •22. Pregnant and lactating women
- •23. Prior recovery from recent infection, including but not limited to COVID 19 within the last 30 days before first dosing with IP
- •24. Known hypersensitivity to macrolides or EP395 or any of the excipients (dicalcium phosphate, croscarmellose sodium, magnesium stearate, microcrystalline cellulose)
- •25. Participation in a study of an experimental drug within 5 half-lives or 3 months before Screening, whichever is longer
- •26. Dependent subjects of the sponsor or investigator (eg, employees, relatives)
- •27. Patients without the capacity to understand the nature and risks of the study
研究者
相似试验
已完成
不适用
A randomised, double-blind, placebo-controlled study evaluating Palmitoylethanolamide for diabetic-related peripheral neuropathic pain, inflammation and quality of lifediabetic-related peripheral neuropathyMetabolic and Endocrine - DiabetesNeurological - Other neurological disordersACTRN12620001302943Gencor Pacific Ltd70
进行中（未招募）
1 期
Intravenous imatinib for corona virus-related lung injury.EUCTR2020-005447-23-NLAmsterdam Universitair Medische Centra, location VUmc90
进行中（未招募）
1 期
Study to evaluate the micro-macroscopic effects on muscles, the safety and tolerability, and the efficacy of givinostat in patients with Becker Muscular DystrophyEUCTR2017-001629-41-NLITALFARMACO S.P.A.48
进行中（未招募）
1 期
A study to test a potential new treatment for COPD patients suffering from the common cold or influenza.Patients with Chronic Obstructive Pulmonary Disease (COPD). In part 1 of the study the patients are in stable state. In part 2 of the study patients have a respiratory virus infection (i.e. cold or flu virus).MedDRA version: 21.1 Level: LLT Classification code 10010953 Term: COPD exacerbation System Organ Class: 100000004855EUCTR2017-003679-75-GBSynairgen Research Limited130
进行中（未招募）
1 期
A four part study to investigate the safety, tolerability and blood levels of single and repeat doses of CHF6297 in healthy volunteers, repeat doses of CHF6297 in patients with COPD and to investigate the anti-inflammatory effect of CHF 6297 after healthy volunteers have been given a challenge agent.Chronic Obstructive Pulmonary DiseaseEUCTR2015-003075-30-GBChiesi Farmaceutici S.p.A.136